IDH1 and central nervous system cancer: Frequently identified oncogenic IDH mutations in glioma are a gain of function that results in the production of 2-hydroxyglutarate (2-HG), an oncometabolite that disrupts cellular metabolism and also affects DNA methylation3,5.